[CG] Addition to VTE risk assessment during pregnancy and postpartum (COVID-19 pandemic, April 2020)
exp date isn't null, but text field is
|Please report any inaccuracies or issues with this guideline using our online form|
COVID-19 infected patients are likely to have an increased risk venous of thromboembolism (VTE) (Driggin et al 2020). Whilst there are no published case series thus far, there are reports of abnormal coagulation parameters in hospitalized patients with severe COVID-19 disease.
It is therefore recommended that:
Antenatal COVID-19 infection should be regarded as a risk factor for VTE during pregnancy, and included in the antenatal risk assessment that occurs at booking and at each antenatal contact (tick the box ‘current systemic infection’).
Antenatal women admitted to hospital with COVID-19 infection should receive thromboprophylaxis with low molecular weight heparin (LMWH) unless there are contraindications, and at least 10 days of prophylactic LMWH, following discharge from hospital.
Postnatal women with COVID-19 infection should receive at least 10 days of prophylactic LMWH following discharge from hospital.”